Cantargia ABCHIX:CANTAS 37 PB Ratio is 4.44 as of Jul. 07, 2026, which is 22% above its 10-year median of 3.63. GuruFocus rates CHIX:CANTAS with a GF Score™ of 37/100. The stock has 2 warning signs investors should review. Among 1,226 Biotechnology companies, Cantargia AB ranks better than 60.85% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-07), Cantargia AB's share price is kr4.174. Cantargia AB's Book Value per Share for the quarter that ended in Mar. 2026 was kr0.94. Hence, Cantargia AB's PB Ratio of today is 4.44.
The historical rank and industry rank for Cantargia AB's PB Ratio or its related term are showing as below:
CHIX:CANTAs'
s PB Ratio Range Over the Past 10 Years
Min: 1.99 Med: 3.63 Max: 5.8
Current: 2.32
During the past 13 years, Cantargia AB's highest PB Ratio was 5.80. The lowest was 1.99. And the median was 3.63.
CHIX:CANTAs's PB Ratio is ranked better than 60.85% of 1226
companies
in the Biotechnology industry
Industry Median: 2.91
vs CHIX:CANTAs: 2.32
During the past 12 months, Cantargia AB's average Book Value Per Share Growth Rate was 234.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -22.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -37.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -6.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Cantargia AB was 117.50% per year. The lowest was -50.10% per year. And the median was 16.15% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cantargia AB PB Ratio Related Terms
Cantargia AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Cantargia AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:CANTAS vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Cantargia AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cantargia AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cantargia AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cantargia AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Cantargia AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cantargia AB (CHIX:CANTAS) has a PB Ratio of 4.44 as of Jul. 07, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cantargia AB and its competitors. This is 22% above median its historical median of 3.63. Over the past decade, Cantargia AB's PB Ratio has ranged from 1.99 to 5.80. According to the industry distribution chart, Cantargia AB ranks #480 out of 1226 companies in the Biotechnology industry, placing it in the top 39.2%.
Is Cantargia AB's PB Ratio too high?
Cantargia AB's current PB Ratio of 4.44 is 22% above median its 10-year median of 3.63. Over the past 10 years, this metric has ranged from a low of 1.99 to a high of 5.80. The Biotechnology industry median PB Ratio is 2.91. Cantargia AB's value of 4.44 is 52.6% above this industry median. Based on the distribution chart, Cantargia AB ranks #480 out of 1226 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cantargia AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Cantargia AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cantargia AB ranks #480 out of 1226 companies for PB Ratio. This puts Cantargia AB in the upper half of its industry. The industry median PB Ratio is 2.91. Cantargia AB's value of 4.44 is 52.6% above this benchmark. Historically, Cantargia AB's own PB Ratio has ranged from 1.99 to 5.80 over the past decade. While the company's 10-year median is 3.63 vs. the industry median of 2.91, Cantargia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.91, based on 1,226 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cantargia AB's current PB Ratio of 4.44 is 52.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cantargia AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cantargia AB's current PB Ratio is 4.44, which is 22% above median its own 10-year median of 3.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantargia AB stock overvalued right now?
Cantargia AB (CHIX:CANTAS) has a current PB Ratio of 4.44. The current PB Ratio is 4.44, which is 22% above median its 10-year median of 3.63 and 52.6% above the Biotechnology industry median of 2.91. Cantargia AB's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cantargia AB (CHIX:CANTAS), the current PB Ratio is 4.44 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
37GF Score
Get the complete analysis for CHIX:CANTAS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CANTAS has been successfully added to your 
